Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Current management in polycythemia vera.

H S Gilbert1

  • 1Albert Einstein College of Medicine, Bronx, NY, USA.

Seminars in Hematology
|March 10, 2001
PubMed
Summary
This summary is machine-generated.

Polycythemia vera (PV) is a myeloproliferative disease causing increased blood cells and risks of thrombosis. Effective platelet-lowering agents like anagrelide, hydroxyurea, and interferon alfa are crucial for managing PV, but combination therapy may be needed.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diagnosis and treatment of thrombocythemia in myeloproliferative disorders.

Oncology (Williston Park, N.Y.)·2001
Same author

Familial myeloproliferative disease.

Bailliere's clinical haematology·2000
Same author

Historical perspective on the treatment of essential thrombocythemia and polycythemia vera.

Seminars in hematology·1999
Same author

Long term treatment of myeloproliferative disease with interferon-alpha-2b: feasibility and efficacy.

Cancer·1998
Same author

Rupture of abdominal aortic aneurysm demonstrated on Tc-99m RBC gastrointestinal bleeding study.

Clinical nuclear medicine·1995
Same author

Polycythaemia vera. III. Burst-forming units-erythroid (BFU-E) response to stem cell factor and c-kit receptor expression.

British journal of haematology·1994
Same journal

Pain in SCD-Many mechanisms and mysteries.

Seminars in hematology·2026
Same journal

The many facets of cardiopulmonary complications in sickle cell disease.

Seminars in hematology·2026
Same journal

Clonal hematopoiesis in the setting of sickle cell disease and its relevance to curative therapies.

Seminars in hematology·2026
Same journal

Treatment of myeloproliferative neoplasms: Exploring new horizons of who and when to cytoreduce in patients with polycythemia vera and essential thrombocytosis.

Seminars in hematology·2026
Same journal

Telomeres biology disorders: the past, the present and the future.

Seminars in hematology·2026
Same journal

Cardiovascular complications in patients with myeloproliferative neoplasms: What hematologists need to know.

Seminars in hematology·2026
See all related articles

Area of Science:

  • Hematology
  • Oncology

Background:

  • Myeloproliferative diseases (MPD) encompass conditions like polycythemia vera (PV), essential thrombocythemia, and chronic myelogenous leukemia.
  • PV is characterized by an overproduction of red blood cells, granulocytes, and platelets, leading to complications such as thrombosis and bleeding.

Purpose of the Study:

  • To review current treatment strategies for polycythemia vera.
  • To evaluate the role of platelet-lowering agents in managing PV complications.

Main Methods:

  • Review of existing literature on PV treatment.
  • Discussion of phlebotomy, antithrombotic therapy, and cytoreductive agents.

Main Results:

  • Phlebotomy is a primary treatment for PV but may necessitate platelet-lowering agents.

Related Experiment Videos

  • Anagrelide, hydroxyurea (HU), and interferon alfa (IFN) are effective in reducing elevated platelet counts.
  • Conventional treatments like radioactive phosphorus and alkylating agents have limitations due to leukemogenicity and mutagenicity.

    • Conclusions:

    • No single cytoreductive agent is sufficient for all PV cases.
    • Future PV treatment protocols should integrate existing drug knowledge for combination therapy.
    • Improved quality of life and survival are goals for advanced PV management.